Dextromethorphan and Quinidine

Brand names: Dextromethorphan Hydrobromide And Quinidine Sulfate · Active ingredient: Dextromethorphan Hydrobromide, Quinidine Sulfate

In short: Dextromethorphan hydrobromide and quinidine sulfate capsules are indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurologic conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying.

Forms & strengthsCapsules: 20 mg of dextromethorphan hydrobromide, USP and 10 mg of quinidine sulfate, USP in an orange opaque capsule printed with and 467 on both cap and body in black ink.
LabelTeva Pharmaceuticals, Inc.
Label updatedSep 16, 2026

What is Dextromethorphan and Quinidine used for?

Dextromethorphan hydrobromide and quinidine sulfate capsules are indicated for the treatment of pseudobulbar affect (PBA).

PBA occurs secondary to a variety of otherwise unrelated neurologic conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state. PBA is a specific condition, distinct from other types of emotional lability that may occur in patients with neurological disease or injury.

Dextromethorphan and Quinidine dosage

The recommended starting dose of dextromethorphan hydrobromide and quinidine sulfate capsules is one capsule daily by mouth for the initial seven days of therapy. On the eighth day of therapy and thereafter, the daily dose should be a total of two capsules a day, given as one capsule every 12 hours.

The need for continued treatment should be reassessed periodically, as spontaneous improvement of PBA occurs in some patients.

How to take Dextromethorphan and Quinidine — instructions & advice from the label

Hypersensitivity

Patients should be advised a hypersensitivity reaction to dextromethorphan hydrobromide and quinidine sulfate could occur. Patients should be instructed to seek medical attention immediately if they experience symptoms indicative of hypersensitivity after taking dextromethorphan hydrobromide and quinidine sulfate capsules .

Cardiac Effects

Patients should be advised to consult their healthcare provider immediately if they feel faint or lose consciousness. Patients should be counseled to inform their healthcare provider if they have any personal or family history of QTc prolongation .

Dizziness

Patients should be advised that dextromethorphan hydrobromide and quinidine sulfate capsules may cause dizziness. Precautions to reduce the risk of falls should be taken, particularly for patients with motor impairment affecting gait or a history of falls .

Drug Interactions

Inform patients that dextromethorphan hydrobromide and quinidine sulfate capsules increases the risk of adverse drug interactions. …

Warnings & precautions

Do not take this medicine if: Dextromethorphan hydrobromide and quinidine sulfate contains quinidine and should not be used concomitantly with other drugs containing quinidine, quinine, or mefloquine.

Dextromethorphan hydrobromide and quinidine sulfate is contraindicated in patients with a history of dextromethorphan hydrobromide and quinidine sulfate, quinine, mefloquine or quinidine-induced thrombocytopenia, hepatitis, bone marrow depression or lupus-like syndrome. Dextromethorphan hydrobromide and quinidine sulfate is also contraindicated in patients with a known hypersensitivity to dextromethorphan (e.g. rash, hives) .

Dextromethorphan hydrobromide and quinidine sulfate is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) or in patients who have taken MAOIs within the preceding 14 days, due to the risk of serious and possibly fatal drug interactions, including serotonin syndrome. Allow at least 14 days after stopping dextromethorphan hydrobromide and quinidine sulfate before starting an MAOI .

Dextromethorphan hydrobromide and quinidine sulfate is contraindicated in patients with a prolonged QT interval, congenital long QT syndrome or a history suggestive of torsades de pointes, and in patients with heart failure .

Dextromethorphan hydrobromide and quinidine sulfate is contraindicated in patients receiving drugs that both prolong QT interval and are metabolized by CYP2D6 (e.g., thioridazine and pimozide), as effects on QT interval may be increased .

Dextromethorphan hydrobromide and quinidine sulfate is contraindicated in patients with complete atrioventricular (AV) block without implanted pacemakers, or in patients who are at high risk of complete AV block.

Quinidine can cause immune-mediated thrombocytopenia that can be severe or fatal. …

Dextromethorphan and Quinidine side effects

A total of 946 patients participated in four Phase 3 controlled and uncontrolled PBA studies and received at least one dose of the combination product of dextromethorphan/quinidine in various strengths at the recommended or higher than the recommended dose. Of those patients, 393 patients were exposed for at least 180 days and 294 patients were exposed for at least one year. Median exposure was 168 days.

Controlled trials enrolled only patients with either ALS or MS. Uncontrolled studies enrolled 136 patients with PBA secondary to a wide variety of underlying neurological conditions including stroke (45 patients) and traumatic brain injury (23 patients). Consequently, patients with other underlying neurologic diseases may experience other adverse reactions not described below.

A 12-week, placebo-controlled study evaluated dextromethorphan hydrobromide and quinidine sulfate 20 mg/10 mg (N=107) and a 30 mg dextromethorphan/10 mg quinidine combination (N=110) compared to placebo (N=109). Approximately 60% of patients had ALS and 40% had MS. Patients were 25 to 80 years of age, with a mean age of approximately 51 years. Three (3) ALS patients in each drug treatment arm and 1 ALS patient in the placebo arm died during the 12-week placebo-control period. All deaths were consistent with the natural progression of ALS. …

Drug interactions

Do not use dextromethorphan hydrobromide and quinidine sulfate with monoamine oxidase inhibitors (MAOIs) or in patients who have taken MAOIs within the preceding 14 days .

Do not use with drugs that both prolong QT interval and are metabolized by CYP2D6 (e.g., thioridazine or pimozide) .

Recommend ECG in patients taking drugs with dextromethorphan hydrobromide and quinidine sulfate that prolong the QT interval and in patients taking concomitant moderate or strong CYP3A4 inhibitors .

Use of dextromethorphan hydrobromide and quinidine sulfate with SSRIs or tricyclic antidepressants increases the risk of ‘serotonin syndrome’ .

The coadministration of dextromethorphan hydrobromide and quinidine sulfate with drugs that undergo extensive CYP2D6 metabolism may result in altered drug effects, due to accumulation of parent drug and/or failure of metabolite formation . Therapy with medications that are primarily metabolized by CYP2D6 and that have a relatively narrow therapeutic index should be initiated at a low dose if a patient is receiving dextromethorphan hydrobromide and quinidine sulfate concurrently. …

About this medicine

Dextromethorphan hydrobromide and quinidine sulfate capsules are an oral formulation of dextromethorphan hydrobromide, USP and quinidine sulfate, USP in a fixed dose combination.

Dextromethorphan hydrobromide, USP is the pharmacologically active ingredient of dextromethorphan hydrobromide and quinidine sulfate capsules that acts on the central nervous system (CNS). The chemical name is dextromethorphan hydrobromide, USP: morphinan, 3-methoxy-17-methyl-, (9α, 13α, 14α), hydrobromide monohydrate. Dextromethorphan hydrobromide, USP has the molecular formula C18H25NO•HBr•H2O with a molecular weight of 370.32. The structural formula is:

Quinidine sulfate, USP is a specific inhibitor of CYP2D6-dependent oxidative metabolism used in dextromethorphan hydrobromide and quinidine sulfate capsules to increase the systemic bioavailability of dextromethorphan. The chemical name is quinidine sulfate, USP: cinchonan-9-ol, 6’-methoxy-, (9S) sulfate (2:1), (salt), dihydrate. Quinidine sulfate dihydrate, USP has the molecular formula of (C20H24N2O2)2•H2SO4•2H2O with a molecular weight of 782.94. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 8ef0fcf1-d0b3-45ae-bd11-479aa7ea8896. Read the full official label on DailyMed.